266 related articles for article (PubMed ID: 21969406)
1. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Klarenbach S; Cameron C; Singh S; Ur E
CMAJ; 2011 Nov; 183(16):E1213-20. PubMed ID: 21969406
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Sabapathy S; Neslusan C; Yoong K; Teschemaker A; Johansen P; Willis M
J Popul Ther Clin Pharmacol; 2016; 23(2):e151-68. PubMed ID: 27463416
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Gu S; Deng J; Shi L; Mu Y; Dong H
J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
8. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
9. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.
Grzeszczak W; Czupryniak L; Kolasa K; Sciborski C; Lomon ID; McEwan P
Diabetes Technol Ther; 2012 Jan; 14(1):65-73. PubMed ID: 22066527
[TBL] [Abstract][Full Text] [Related]
14. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
Granström O; Bergenheim K; McEwan P; Sennfält K; Henriksson M
Prim Care Diabetes; 2012 Jul; 6(2):127-36. PubMed ID: 22001114
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Beale S; Bagust A; Shearer AT; Martin A; Hulme L
Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL; Sauriol L; Minshall ME
Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
[TBL] [Abstract][Full Text] [Related]
19. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
[TBL] [Abstract][Full Text] [Related]
20. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.
McIntosh B; Cameron C; Singh SR; Yu C; Dolovich L; Houlden R
Open Med; 2012; 6(2):e62-74. PubMed ID: 23696771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
